A Phase II Study of Gemcitabine and Docetaxel Therapy in Patients with Advanced Urothelial Carcinoma

Cancer

Volumn 98, Issue 9, 2003, Pages 1863-1869

  Gitlitz, Barbara J ^a,b   Baker, Carole ^a   Chapman, Yvonne ^a   Allen, Heather J ^a   Bosserman, Linda D ^a   Patel, Ravi ^a   Sanchez, James D ^a   Shapiro, Richard M ^a   Figlin, Robert A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Advanced urothelial carcinoma; Docetaxel; Gemcitabine; Toxicity

Indexed keywords

CISPLATIN; DOCETAXEL; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; INOPERABLE CANCER; MALE; MULTICENTER STUDY; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT INDICATION; TREATMENT OUTCOME; URINARY TRACT CARCINOMA; UROTHELIUM;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; DEOXYCYTIDINE; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; TAXOIDS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 0142150098     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11726     Document Type: Article

References (11)

1. Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a Phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1997;15:2564-2570.
2. Stadler WM, Kuzel TM, Rahgavan D, et al. Metastatic bladder cancer: advances in therapy. Eur J Cancer. 1997;33(Suppl 1):523-526.
3. Bellmunt J, Guillen V, Paz-Ares L, et al. Gemcitabine/paclitaxel-based three drug regimens in advanced urothelial cancer. Eur J Cancer. 2000;36(Suppl 2):17-22.
4. Georgoulias V, Papadakis E, Alexopoulos A, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small cell lung cancer: a randomised, multicentre trial. Lancet. 2001;357:1478-1484.
5. Georgoulias V, Scagliotti G, Miller V, et al. Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer. Semin Oncol. 2001;28(Suppl 2):15-21.
6. Meluch AA, Burris HS, Greco FA, et al. Gemcitabine and paclitaxel combination therapy in transitional cell carcinoma of the urothelium. Eur J Cancer. 2000;36(Suppl 2):30-33.
7. Sternberg CN, Calabro F, Pizzocaro G, et al. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer. 2001;92:2993-2998.
8. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. J Clin Oncol. 2000;18:3068-3077.
9. Kaufman D, Raghavan D, Carducci M, et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol. 2000;18:1921-1927.
10. Caries J, Nogue M. Gemcitabine/carboplatin in advanced urothelial cancer. Semin Oncol. 2001;28(Suppl 10):19-24.
11. Meluch AA, Greco FA, Burris HA III, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a Phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2001;19:3018-3024.